Date: This event took place on May 15, 2018
Custom webcast sponsor retains sole responsibility for content.
Type I interferons (IFNs) are essential mediators of antiviral responses and have been implicated in the pathogenesis of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermatomyositis, as well as monogenic type I interferonopathies.
Despite this fundamental role in health and disease, the direct quantification of type I IFNs has been challenging until recently with proxy readouts such as gene expression utilized instead.
Using single-molecule array (Simoa) digital ELISA technology, coupled with high-affinity autoantibodies isolated from patients with biallelic mutations in the AIRE protein causing APS1/APECED, we are able to detect attomolar concentrations of IFNα in patient samples. Importantly, these antibodies enabled detection of all 13 IFN- α subtypes, and protein measurements correlated well with functional activity and IFN-stimulated gene expression. High circulating IFNα levels were associated with increased clinical severity in SLE patients, and a study of the cellular source of IFNα protein indicated disease-specific mechanisms.
Measurement of IFNα attomolar concentrations by digital ELISA is enhancing our understanding of IFN biology and potentially improve the diagnosis and stratification of pathologies associated with IFN dysregulation, while providing novel tools to assess new therapeutic strategies.
During this webcast you will learn/our speaker(s) will address:
- How digital ELISA enables direct quantification of IFNa protein in human samples
- How application of this assay to different diseases enables a better classification of autoimmune diseases and potential patient stratification
- Such low protein sensitivity can identify the cellular driver of autoimmune states
Unable to join the live event? Watch on-demand. Register now to ensure that you receive information on how to gain access after the live event.
Dr. Darragh Duffy, Institut Pasteur, Paris
Throughout my research career I have been interested in how a better understanding of fundamental immunology can be applied to novel solutions for improving human health. I undertook a PhD in immunological memory, and with progression of my career moved closer to translational research to deliver research findings to the clinic. More recently I have focused on the discovery and translation of immune biomarkers that can help with disease diagnosis or to manage therapeutic decisions. My current focus as scientific manager of the LabEx Milieu Interieur project at Institut Pasteur, Paris is to understand the genetic and environmental determinants of a healthy immune response, and also apply these findings to disease settings to develop new diagnostic and therapeutic approaches.
Moderator: Dr Jayshan Carpen, Springer Nature
Jayshan is a Senior Publishing Manager for Springer Nature and oversees the custom multimedia unit. Previously he ran science events at the Royal Institution of Great Britain. He received his PhD from the University of Surrey, UK in Neurogenetics. His doctoral thesis focused on identifying polymorphisms associated with diurnal preference and circadian sleep disorders.